H.C. Wainwright Reaffirms Their Buy Rating on Protagonist Therapeutics (PTGX)

Tip Ranks
2025.11.14 23:38
portai
I'm PortAI, I can summarize articles.

H.C. Wainwright analyst Douglas Tsao reaffirmed a Buy rating for Protagonist Therapeutics with a price target of $80.00. Tsao, who covers the Healthcare sector, has an average return of 22.0% and a 53.85% success rate. Citi's Geoff Meacham also issued a Buy rating, while TR | OpenAI reiterated a Hold rating on Protagonist Therapeutics.

H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Protagonist Therapeutics today and set a price target of $80.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Tsao covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Hansa Biopharma AB, and Alkermes. According to TipRanks, Tsao has an average return of 22.0% and a 53.85% success rate on recommended stocks.

In addition to H.C. Wainwright, Protagonist Therapeutics also received a Buy from Citi’s Geoff Meacham in a report issued on November 10. However, on November 11, TR | OpenAI – 4o reiterated a Hold rating on Protagonist Therapeutics (NASDAQ: PTGX).

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer